Features of use of prepared medicinal forms of insulin in diabetes

Authors

  • S.V. Mamonov National Aviation University
  • L.R. Reshetnyak National Aviation University

DOI:

https://doi.org/10.18372/2306-6407.2.18050

Keywords:

insulin, glargine, glucose, long-acting drugs, production

Abstract

Diabetes mellitus, which is the third most common disease in the world, requires the development of affordable domestic recombinant insulin. Insulin plays a key role in ensuring normal glucose metabolism in the body. Long-acting and short-acting insulin are used to mimic physiological insulin secretion and control blood glucose levels. Long-acting insulin is injected into the thigh, while short-acting insulin is injected into the abdomen. Ultra-short-acting drugs begin to act quickly and have a short time of elimination from the body. Insulin glargine, a representative of long-acting insulin, is distinguished by a constant rate of release and the absence of hypoglycemia. There are also combined insulins for the treatment of type 2 diabetes that combine long-acting and short-acting insulins in one drug, facilitating convenient administration.

References

Opie E. L. The relation of diabetes mellitus to lesions of the pancreas. hyaline degeneration of the islands oe langerhans // Journal of experimental medicine. – 1901. – Vol. 5, no. 5. – P. 527–540. https://doi.org/10.1084/jem.5.5.527

Opie E. L. On the relation of chronic interstitial pancreatitis to the islands of langerhans and to diabetes melutus // Journal of experimental medicine. – 1901. – Vol. 5, no. 4. – P. 397–428. https://doi.org/10.1084/jem.5.4.397

Heinemann L., Owens D. Biosimilar Insulin and Insulin Antibodies // Journal of Diabetes Science and Technology. – 2013. – Vol. 7, no. 4. – P. 806–807. https://doi.org/10.1177/193229681300700401

Sommerfeld M. R., et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites // PLoS ONE. – 2010. – Vol. 5, no. 3. – P. e9540. https://doi.org/10.1371/journal.pone.0009540

Lucidi P., et al. Glargine metabolism over 24h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study // Nutrition, metabolism and cardiovascular diseases. – 2014. – Vol. 24, no. 7. – P. 709–716. https://doi.org/10.1016/j.numecd.2014.02.008

Published

2023-12-12

Issue

Section

Reviews